412268-99-6

Usage

Uses

Used in Organic Chemistry Research:
3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is used as a research compound in organic chemistry for its potential as a building block in the synthesis of various pharmaceuticals and bioactive molecules. Its unique structure and functional groups make it a versatile starting material for the development of new drugs or materials with specific properties.
Used in Pharmaceutical Development:
In the Pharmaceutical Industry, 3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is used as a key intermediate in the synthesis of new drugs. Its sulfonamide functional group and other structural features contribute to the development of molecules with specific biological and pharmacological activities, making it an interesting compound for further investigation and development.
Used in Bioactive Molecule Synthesis:
3-(3-Phenylsulfamoylphenyl)acrylic acid methyl ester is utilized as a precursor in the synthesis of bioactive molecules. Its potential biological and pharmacological activities make it a valuable compound for creating molecules with therapeutic or diagnostic applications, further expanding its use in the life sciences and medicine.

Upstream product

• 2905-24-0 3-Bromobenzenesulfonyl chloride 
• 62-53-3 aniline 
• 292638-85-8 acrylic acid methyl ester 
• 166338-06-3 N-phenyl-3-bromo-benzenesulfonamide 
• 659-04-1 methyl 3-nitrocinnamate 
• 99-61-6 3-nitro-benzaldehyde 
• 58186-45-1 3-(3-amino-phenyl)-acrylic acid methyl ester 
• 100-52-7 benzaldehyde 
• 610801-83-7 methyl (2E)-3-[3-(chlorosulfonyl)phenyl]prop-2-enoate 

Relevant academic research and scientific papers

COMPOUNDS AND METHODS FOR TREATING CANCER

Substituted cinnamamide compounds and analogs, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds to treat, prevent or ameliorate cancer are provided.

SOLID STATE FORMS OF (2E)-N-HYDROXY-3-[3-(PHENYLSULFAMOYL)PHENYL]PROP-2-ENAMIDE AND PROCESS FOR PREPARATION THEREOF

The Present invention relates to solid state forms of (2E)-N-hydroxy-3-[3-(N-phenyl sulfamoyl)phenyl]prop-2-enamide represented by the following structural formula-1 and process for the preparation thereof.

POLYMORPHIC FORMS OF BELINOSTAT AND PROCESSES FOR PREPARATION THEREOF

The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Simple and efficient synthesis of belinostat

A novel synthesis of belinostat (1) starting from 3-nitrobenzaldehyde has been developed. The key step in this sequence involves the conversion of (2E)-3-(3-aminophenyl)acrylic acid methyl ester to (2E)-3-(3- chlorosulfonylphenyl)acrylic acid methyl ester via diazotization and sulfonylation. Taylor & Francis Group, LLC.

Novel sulfonamide derivatives as inhibitors of histone deacetylase

Inhibition of the enzyme histone deacetylase (HDAC) is emerging as a novel approach to the treatment of cancer. A series of novel sulfonamide derivatives were synthesized and evaluated for their ability to inhibit human HDAC. Compounds were identified which are potent enzyme inhibitors, with IC 50 values in the low nanomolar range against enzyme obtained from HeLa cell extracts, and with antiproliferative effects in cell culture. Extensive characterization of the structure - activity relationships of this series identified key requirements for activity. These include the direction of the sulfonamide bond and substitution patterns on the central phenyl ring. The alkyl spacer between the aromatic head group and the sulfonamide functionality also influenced the HDAC inhibitory activity. One of these compounds, m11.1, also designated PXD101, has entered clinical trials for solid tumors and haematological malignancies.

Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors

This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: —S (═O)2NR1— and —NR1S(═O)2—; R1 is a sulfonamido substituent; and, Q2 is an acid leader group; with the proviso that if J is —S(═O)2NR1—, then Q1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis.